AZN

AstraZeneca PLC [AZN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AZN Stock Summary

Top AZN Correlated Resources

AZN


Top 10 Correlated ETFs

AZN


Top 10 Correlated Stocks

AZN


In the News

05:10 04 Dec 2022 AZN

2 Stocks That Could Surprise Investors in 2023

Investing in safe healthcare stocks may be an underrated strategy to deploy.

09:47 04 Dec 2022 AZN

AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal

The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.

04:06 04 Dec 2022 AZN

AstraZeneca sells Ohio manufacturing plant to National Resilience

AstraZeneca PLC (LSE:AZN) said it has sold its manufacturing site in West Chester, Ohio to National Resilience, Inc., which plans to expand the site and support future growth of its medicines manufacturing capabilities.  "As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio,” commented Andrew Wirths, senior vice president of AstraZeneca's Americas Supply Region.

03:35 04 Dec 2022 AZN

AstraZeneca adds focus on personalised cancer cell therapy with US$320mln acquisition

AstraZeneca PLC (LSE:AZN) will spend up to US$320mln to strengthen its cancer business with an acquisition specialising in an innovative cell therapy approach for hard-to-treat cancers. Amsterdam-based Neogene Therapeutics Inc focuses on next-generation T-cell receptor therapies (TCR-Ts) to treat patients with advanced solid tumours.

03:20 04 Dec 2022 AZN

C4X Discovery signs exclusive global licence with AstraZeneca

C4X Discovery Holdings PLC (AIM:C4XD) (C4XD) has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to US$402mln, for developing and commercialising its NRF2 Activator programme.   AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).

11:17 04 Dec 2022 AZN

Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

09:46 04 Dec 2022 AZN

AstraZeneca vaccine found to be 79% effective in U.S. study

Dr. David Levy, CEO of EHE Health, joins Worldwide Exchange on the news that AstraZeneca's Covid-19 vaccine has been found to be 79% effective in a U.S. study.

09:37 04 Dec 2022 AZN

2 Stocks to Buy Whether or Not a Recession Is Coming

Both have outperformed the stock market this year.

11:18 04 Dec 2022 AZN

AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use

The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.

03:48 04 Dec 2022 AZN

AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod

AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.

AZN Financial details

Company Rating
Strong Buy
Market Cap
212.19B
Income
27M
Revenue
44.25B
Book val./share
11.35
Cash/share
1.58
Dividend
1.42
Dividend %
2.07%
Employees
83.1K
Optionable
Yes
Shortable
Yes
Earnings
-
P/E
-190.19
Forward P/E
21.36
PEG
18.94
P/S
4.79
P/B
6.03
P/C
43.25
P/FCF
32.88
Quick Ratio
0.2
Current Ratio
0.81
Debt / Equity
0.67
LT Debt / Equity
0.67
-
-
EPS (TTM)
-0.01
EPS next Y
3.2
EPS next Q
0.77
EPS this Y
-96.72%
EPS next Y
-64000%
EPS next 5Y
-64000%
EPS last 5Y
-49.22%
Revenue last 5Y
10.74%
Revenue Q/Q
-3.58%
EPS Q/Q
324%
-
-
-
-
SMA20
14.09%
SMA50
14.05%
SMA100
-0.05%
Inst Own
32.62%
Inst Trans
-3.66%
ROA
-
ROE
-
ROC
-
Gross Margin
66%
Oper. Margin
-
Profit Margin
-
Payout
16283%
Shs Outstand
3.1B
Shs Float
3.09B
-
-
-
-
Target Price
78
52W Range
52.65-71.7
52W High
-3.75%
52W Low
+31.42%
RSI
78.55
Rel Volume
0.64
Avg Volume
6.14M
Volume
3.96M
Perf Week
4.45%
Perf Month
25.37%
Perf Quarter
10.6%
Perf Half Y
2.8%
-
-
-
-
Beta
0.168156
-
-
Volatility
0.93%, 3.97%
Prev Close
0.54%
Price
68.34
Change
1.49%

AZN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
8.878.729.3710.1413.19
Net income per share
1.190.850.511.220.04
Operating cash flow per share
1.411.031.141.832.1
Free cash flow per share
0.770.490.20.841.33
Cash per share
1.762.212.393.052.26
Book value per share
5.914.925.045.9513.85
Tangible book value per share
-8.44-7.74-6.88-6.54-8.14
Share holders equity per share
5.914.925.045.9513.85
Interest debt per share
7.578.087.548.2511.3
Market cap
90.52B91.1B127.73B132.77B168.17B
Enterprise value
105.1B105.47B140.59B145.32B192.63B
P/E ratio
30.1642.2795.6841.541.5K
Price to sales ratio
4.034.125.244.994.49
POCF ratio
25.334.843.0227.6728.2
PFCF ratio
46.2373.05250.9560.5444.69
P/B Ratio
6.057.319.738.54.28
PTB ratio
6.057.319.738.54.28
EV to sales
4.684.775.775.465.15
Enterprise value over EBITDA
15.5614.6120.6117.3225.55
EV to operating cash flow
29.3740.2847.3530.2832.3
EV to free cash flow
53.6784.58276.2166.2751.19
Earnings yield
0.030.020.010.020
Free cash flow yield
0.020.0100.020.02
Debt to equity
1.041.391.241.150.74
Debt to assets
0.740.770.760.770.63
Net debt to EBITDA
2.161.991.891.53.24
Current ratio
0.80.960.860.961.16
Interest coverage
2.72.482.094.060.83
Income quality
1.191.212.221.553.24
Dividend Yield
0.040.040.030.030.02
Payout ratio
1.171.622.691.1234.43
Sales general and administrative to revenue
0.460000
Research and developement to revenue
0.260.270.250.230.26
Intangibles to total assets
0.60.560.530.490.59
Capex to operating cash flow
-0.45-0.52-0.83-0.54-0.37
Capex to revenue
-0.07-0.06-0.1-0.1-0.06
Capex to depreciation
-0.53-0.37-0.65-0.83-0.34
Stock based compensation to revenue
00000
Graham number
12.559.77.6312.773.51
ROIC
0.080.080.070.110.01
Return on tangible assets
0.120.080.050.090
Graham Net
-16.09-15.61-14.98-15.66-19.46
Working capital
-3.23B-701M-2.55B-763M3.65B
Tangible asset value
-21.37B-19.62B-17.91B-17.15B-23.1B
Net current asset value
-33.56B-31.02B-31.22B-31.55B-39.83B
Invested capital
1.191.531.391.30.78
Average receivables
00000
Average payables
2.98B2.04B2.06B2.35B2.59B
Average inventory
3.53B3.46B3.61B4.02B6.5B
Days sales outstanding
00000
Days payables outstanding
305.24127.19131.58161.8782.88
Days of inventory on hand
256.55213.71236.83277.18263.63
Receivables turnover
00000
Payables turnover
1.22.872.772.254.4
Inventory turnover
1.421.711.541.321.38
ROE
0.20.170.10.20
Capex per share
-0.64-0.54-0.95-0.99-0.78

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-09-30
Revenue per share
3.133.33.883.683.55
Net income per share
0.21-0.55-0.110.120.53
Operating cash flow per share
0.340.570.461.040.95
Free cash flow per share
0.210.350.230.930.59
Cash per share
5.962.392.071.881.58
Book value per share
5.9713.2812.6911.7411.35
Tangible book value per share
-6.14-8.11-7.47-8.03-7.8
Share holders equity per share
5.9713.2812.6911.7411.35
Interest debt per share
10.610.7810.0510.159.57
Market cap
157.18B179.7B180.23B205.39B169.78B
Enterprise value
169.11B204.54B204.68B230.73B194.63B
P/E ratio
71.44-27.19-129.85133.0225.88
Price to sales ratio
19.1218.2115.0118.0315.46
POCF ratio
176.21104.54127.163.5557.95
PFCF ratio
291.61169.69257.4771.5993.34
P/B Ratio
10.034.524.595.654.83
PTB ratio
10.034.524.595.654.83
EV to sales
20.5720.7317.0420.2617.72
Enterprise value over EBITDA
91.76182.47109.63105.0775.06
EV to operating cash flow
189.58118.99144.3471.3966.43
EV to free cash flow
313.74193.15292.480.42107
Earnings yield
0-0.01000.01
Free cash flow yield
00.0100.010.01
Debt to equity
1.570.730.740.790.67
Debt to assets
0.790.630.630.640.63
Net debt to EBITDA
6.4722.1613.111.549.58
Current ratio
1.231.131.1610.81
Interest coverage
3.46-5-0.942.613.67
Income quality
1.62-1.04-4.098.371.79
Dividend Yield
00.0100.010.01
Payout ratio
0-0.8407.70.85
Sales general and administrative to revenue
00000
Research and developement to revenue
0.220.220.350.190.21
Intangibles to total assets
0.430.60.590.610.63
Capex to operating cash flow
-0.4-0.38-0.51-0.11-0.38
Capex to revenue
-0.04-0.07-0.06-0.03-0.1
Capex to depreciation
-0.47-0.24-0.33-0.28-0.83
Stock based compensation to revenue
00000
Graham number
5.3112.855.665.7411.63
ROIC
0.02-0.0200.010.02
Return on tangible assets
0.01-0.04-0.010.010.05
Graham Net
-15.22-18.35-17.84-17.53-16.66
Working capital
5.05B3.04B3.65B-93M-4.63B
Tangible asset value
-16.11B-24.27B-23.1B-24.87B-24.14B
Net current asset value
-30.67B-40.62B-39.83B-41.27B-38.81B
Invested capital
1.750.80.780.860.83
Average receivables
00000
Average payables
17.8B18.26B10.34B17.86B17.78B
Average inventory
6.19B9.08B8.3B7.62B6.35B
Days sales outstanding
00000
Days payables outstanding
728.26447.0854.95457.92534.02
Days of inventory on hand
195.61252.2174.8195.43153.26
Receivables turnover
00000
Payables turnover
0.120.21.640.20.17
Inventory turnover
0.460.360.510.460.59
ROE
0.04-0.04-0.010.010.05
Capex per share
-0.13-0.22-0.23-0.12-0.36

AZN Frequently Asked Questions

What is AstraZeneca PLC stock symbol ?

AstraZeneca PLC is a GB stock and trading under the symbol AZN

Is AstraZeneca PLC buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $76.5. The lowest prediction is $75 and the highest is $78

What is AZN stock prediction ?

With a median analyst target price of $78, 1 stock analysts have made 1 forecasts in last 90 days. $78 is the lowest and $78 is the greatest projection.

What is AstraZeneca PLC stock quote today ?

AstraZeneca PLC stock price is $68.34 today.

Is AstraZeneca PLC stock public?

Yes, AstraZeneca PLC is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap